Abstract: Certain transcription factors (enhancer binding proteins) significantly increase transcription rates from genes by nicking a single DNA strand in the vicinity of their DNA binding sites, thereby allowing RNA polymerase to gain access to the transcribed DNA strand by a process of “threading”. DNA template nicking is a detectable and quantifiable byproduct indicative of transcriptional activation that can be used to design practical assays. These assays are used to determine which transcription factors (enhancer binding proteins) are actively catalyzing the transcription of a gene in any cell type, or in any cell in response to any drug or treatment. This group of transcription factors have a predictable molecular biological activity in addition to transcription activation, namely site-specific DNA strand cleavage.

Abstract: A central role for the gene encoding dopamine beta-hydroxylase in neuropsychiatric disorders is disclosed. Use of single nucleotide polymorphisms in the dopamine beta-hydroxylase gene for diagnosis, prediction of clinical course and treatment response, development of new treatments and development of cell-culture based and animal models for research and treatment are disclosed.

Abstract: This invention is directed to a rapid and simple method for determining organisms and/or cells in a sample. Generally, the method is directed to the use of molecular probes to selectively stain the organisms and/or cells for determination wherein growth medium, fixative reagents and/or excess molecular probes need not be separated before a determination is made.

Abstract: The invention relates to the discovery that a putative gene of Mycobacterium tuberculosis with no previously identified function is responsible for the ability of the bacterium to activate thioamide drugs. Since M. tuberculosis has a low rate of synonymous mutations, all mutations in this gene, identified as Rv3854c and now termed “EtaA,” are expected to inhibit the ability of a bacterium with the mutation to activate a thioamide or thiocarbonyl drug. Thus, detecting a bacterium with a mutation in this gene indicates that the bacterium is resistant to treatment with thioamides.

Abstract: The present invention provides methods for determining the methylation status of CpG-containing dinucleotides on a genome-wide scale using infrequent cleaving, methylation sensitive restriction endonucleases and two-dimensional gel electrophoretic display of the resulting DNA fragments. Such methods can be used to diagnose cancer, classify tumors and provide prognoses for cancer patients. The present invention also provides isolated polynucleotides and oligonucleotides comprising CpG dinucleotides that are differentially methylated in malignant cells as compared to normal, non-malignant cells. Such polynucleotides and oligonucleotides are useful for diagnosis of cancer. The present invention also provides methods for identifying new DNA clones within a library that contain specific CpG dinucleotides that are differentially methylated in cancer cells as compared to normal cells.

Abstract: The present invention provides oligonucleotides for detecting Salmonella toxin gene invA mRNA and stn mRNA which oligonucleotides specifically bind to invA mRNA or stn mRNA at a relatively low temperature (for example, 41° C.) and at a constant temperature, and a process of amplifying Salmonella toxin gene invA mRNA or stn mRNA and a method of detecting the same using the oligonucleotides.

Abstract: This invention relates to an improved process for detecting and quantifying a desired nucleic acid sequence. The process involves synthesizing single stranded RNA, single stranded DNA, double-stranded DNA followed by detection using an electrochemiluminescent labeled binding species.

Abstract: The invention provides purified and isolated DNA fragments from Bacillus anthracis chromosomal DNA, primer sets and probes derived therefrom, as well as kits and detection methods for B. anthracis. The methods of the invention provide for specific detection of anthrax over closely related strains of Bacillus, as well as accurate detection of low numbers of B. anthracis in an environmental sample containing large amounts of non-specific DNA. The invention is applicable to food, health care, and military applications.

Abstract: The present invention compares expression profiles from matched samples to identify differential gene expression. Samples are matched according to physiological, pharmacological and/or disease state. Comparison of matched samples eliminates gene expression differences that are the result of changes in variables that are not of interest. The gene expression differences that remain can be attributed with a high degree of confidence to the unmatched variation. The gene expression differences thus identified can be used for example to diagnose disease, identify physiological state, design drugs, and monitor therapies.

Abstract: The invention relates to an affinity sensor for detecting specific molecular binding events, for use in the field of molecular biology, e.g., in medical diagnostics, especially in biosensor technology or in DNA microarreay tests. The aim of the invention is to provide an affinity sensor of this type for rapidity, sensitively, specifically, economically and routinely detecting the presence of molecules, especially bioactive molecules, and to provide special applications for an affinity sensor of this type. To this end, the affinity sensor consists of a support substrate which is provided with at least two electrodes. The electrodes are situated equidistantly from each other and cover an area on both sides, at least this area being provided for receiving immobilized specific binding partners which are capable of coupling complementary corresponding binding partners directly or with other specific binding molecules.

Abstract: The invention provides novel polypeptides which are associated with the transcription complex NF-AT, polynucleotides encoding such polypeptides, antibodies which are reactive with such polypeptides, polynucleotide hybridization probes and PCR amplification probes for detecting polynucleotides which encode such polypeptides, transgenes which encode such polypeptides, homologous targeting constructs that encode such polypeptides and/or homologously integrate in or near endogenous genes encoding such polypeptides, nonhuman transgenic animals which comprise functionally disrupted endogenous genes that normally encode such polypeptides, and transgenic nonhuman animals which comprise transgenes encoding such polypeptides.

Abstract: The present invention provides methods for determining cancer susceptibility in a human subject by identifying in a nucleic acid sample from the subject, a nucleotide occurrence of a single nucleotide polymorphism (SNP) of the STK15 gene, including the STK15 Ile31 polymorphism. The invention provides isolated polynucleotides, polypeptides, specific binding pair members, and cells useful for identifying agents that affect tumor susceptibility. Furthermore, the invention provides methods for detecting low penetrance tumor susceptibility genes.

Abstract: The present invention relates to means for the detection and characterization of nucleic acid sequences, as well as variations in nucleic acid sequences. The present invention also relates to methods for forming a nucleic acid cleavage structure on a target sequence and cleaving the nucleic acid cleavage structure in a site-specific manner. The structure-specific nuclease activity of a variety of enzymes is used to cleave the target-dependent cleavage structure, thereby indicating the presence of specific nucleic acid sequences or specific variations thereof. The present invention further relates to methods and devices for the separation of nucleic acid molecules based on charge. The present invention also provides methods for the detection of non-target cleavage products via the formation of a complete and activated protein binding region. The invention further provides sensitive and specific methods for the detection of nucleic acid from various viruses in a sample.

Abstract: The present invention relates to a peptide nucleic acid probe-based method for generating data indicative of the presence of a nucleotide polymorphism, mutation, or methylated cytosine in a nucleotide containing compound. A peptide nucleic acid probe (PNAP) is subjected to temperature gradient electrophoresis in the presence of a nucleotide containing compound. The PNAP is irradiated to generate a spectroscopic signal. The spectroscopic signal is converted into data suitable for determining the presence of the nucleotide polymorphism or the mutation in the nucleotide-containing compound.

Abstract: The present invention provides new methods for detecting, diagnosing, monitoring, staging, prognosticating, imaging and treating lung cancer.

Abstract: The present invention provides a multiplex RT-PCR/PCR method, which enables in a single assay the simultaneous detection of any combination of bovine rotavirus, bovine coronavirus, Cryptosporidium parvum, and optionally, Escherichia coli strains producing K99 pili or heat-stable enterotoxin STa.

Abstract: This invention relates to devices, methods, and compositions of matter for the multiplex amplification and analysis of nucleic acid sequences in a sample using ligation-dependent strand displacement amplification technologies in combination with bioelectronic microchip technology.

Abstract: A novel polymorphic site in the 5? leader cistron of the ?2-adrenergic receptor (?2AR) gene is disclosed. The polymorphisms present at this site result in different levels of inhibition of translation of ?2AR mRNA. Compositions and methods for genotyping this polymorphic site as disclosed. In addition, methods for using this genotype information are disclosed, including predicting genetic predisposition to a disease modified by ?2AR expression and predicting a patient's bronchodilating response to ?2-agonists.

Abstract: A process for detecting a complementary DNA fragment is performed utilizing a DNA micro-array, a radiation image storage panel containing a stimulable phosphor, and a spacer sheet having plural openings.

Abstract: There is a tremendous need for high throughput gene expression technology which can efficiently and cheaply identify and accurately isolate different genes expressed between diseased and normal tissues for use in discovering new drugs. The present invention utilizes a combination of biomolecular chemistry methods to eliminate/degrade redundant sequences and fluorescence dye assay to identify these unique sequences from two cell or tissue populations. cDNA from normal or diseased cells or tissues are hybridized with the RNA of the complement normal or diseased cells or tissues. The hybridized cDNA/RNA is incubated with exonucleases, resulting in degradation of all but the single stranded RNA and DNA. RNA are then eliminated using RNase and the remaining DNA which are unique to the sample are amplified.